As part of the deal JSR took a minority stake in BIA.

JSR and BIA Separations entered a partnership that includes JSR taking a minor equity position on November 14, 2011. The companies started a joint global marketing and sales effort as well as collaborative R&D activities in the area of downstream purification to aid in the manufacture of vaccines, DNA, and antibody-based medicines.

Through this arrangement JSR gains access to BIA Separations’ downstream purification technology. BIA’s technology will be combined with JSR’s Protein A media. BIA expects JSR’s global presence and expertise in the field of consistent high-quality volume manufacturing will help it successfully grow its business.

JSR is headquartered in Tokyo and has factories and offices in Europe, the U.S., China, Taiwan, Korea, and Singapore. BIA Separations claims to be the only worldwide developer and manufacturer of CIM Convective Interaction Media®, short monolithic chromatographic columns optimized for the separation and purification of large biomolecules and viral particles on the laboratory and industrial scale.

Previous articleMyriad Genetics Nabs RAD51C Gene for Hereditary Breast and Ovarian Cancer Testing
Next articleStudies Show Pancreatic Cancer Starts to Spread Before Initial Tumor is Evident